Kyoichi Kaira1,2, Ichiro Naruse2, Shu Shinomiya3, Hiroshi Kagamu3. 1. Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan kkaira1970@yahoo.co.jp. 2. Department of Respiratory Medicine, Hidaka Hospital, Gunma, Japan. 3. Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.
Abstract
BACKGROUND: Limited information is available on the occurrence of synchronous malignancy in patients with advanced thymic cancer (TC) who have achieved long-term survival due to sequential chemotherapy. Here, we present two cases of hematological malignancies in long-term survivors with advanced TC. CASE REPORTS: A 56-year-old man underwent surgical resection following the diagnosis of TC with a histological indication of squamous cell carcinoma. He received sequential chemotherapy, including carboplatin plus paclitaxel, amrubicin, and S-1, due to multiple pulmonary metastases. After >4 years of first-line chemotherapy, he developed consistent myelosuppression and a definite diagnosis of acute promyelocytic leukemia was made following bone marrow analysis. A 49-year-old man with advanced TC received carboplatin plus paclitaxel with amrubicin as second-line therapy due to recurrence. Amrubicin was administered for 54 cycles but T-cell lymphoblastic lymphoma without recurrence of TC was confirmed following transbronchial nodal biopsy due to marked lymphadenopathy. CONCLUSION: Physicians should be alert to the occurrence of hematological malignancy in patients with thymic cancer. Copyright
BACKGROUND: Limited information is available on the occurrence of synchronous malignancy in patients with advanced thymic cancer (TC) who have achieved long-term survival due to sequential chemotherapy. Here, we present two cases of hematological malignancies in long-term survivors with advanced TC. CASE REPORTS: A 56-year-old man underwent surgical resection following the diagnosis of TC with a histological indication of squamous cell carcinoma. He received sequential chemotherapy, including carboplatin plus paclitaxel, amrubicin, and S-1, due to multiple pulmonary metastases. After >4 years of first-line chemotherapy, he developed consistent myelosuppression and a definite diagnosis of acute promyelocytic leukemia was made following bone marrow analysis. A 49-year-old man with advanced TC received carboplatin plus paclitaxel with amrubicin as second-line therapy due to recurrence. Amrubicin was administered for 54 cycles but T-cell lymphoblastic lymphoma without recurrence of TC was confirmed following transbronchial nodal biopsy due to marked lymphadenopathy. CONCLUSION: Physicians should be alert to the occurrence of hematological malignancy in patients with thymic cancer. Copyright
Authors: Jessica A Hellyer; Matthew A Gubens; Kristen M Cunanan; Sukhmani K Padda; Matthew Burns; A John Spittler; Jonathan W Riess; Melanie San Pedro-Salcedo; Kavitha J Ramchandran; Joel W Neal; Heather A Wakelee; Patrick J Loehrer Journal: Lung Cancer Date: 2019-09-18 Impact factor: 5.705
Authors: Girum L Lemma; Ju-Whei Lee; Seena C Aisner; Corey J Langer; William J Tester; David H Johnson; Patrick J Loehrer Journal: J Clin Oncol Date: 2011-04-18 Impact factor: 44.544